In this field, only a secondary analysis of the Sapphire study for NephroCheck® ([TIMP-2]×[IGFBP7]), known as the cell cycle arrest biomarker, showed that a result of >2 was equivalent to AKI stage progression on the risk of ESKD or death at 9 months (16). This evidence concerns the gene IGFBP7 and acute kidney injury.